ScholarIQanswers from OpenAlex & ORCID
M. Catherine Pietanza
ResearcherPublications, citations & collaboration network
M. Catherine Pietanza is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does M. Catherine Pietanza have?
ScholarIQindexed works
M. Catherine Pietanza has 183 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does M. Catherine Pietanza have?
ScholarIQcitation count
M. Catherine Pietanza has 23,734 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of M. Catherine Pietanza?
ScholarIQh-index
M. Catherine Pietanza has an h-index of 56 in OpenAlex.
What is the i10-index of M. Catherine Pietanza?
ScholarIQi10-index
M. Catherine Pietanza has an i10-index of 96 in OpenAlex.
What is the ORCID of M. Catherine Pietanza?
ScholarIQorcid
The ORCID for M. Catherine Pietanza is on the source record.
What is the OpenAlex record for M. Catherine Pietanza?
ScholarIQopenalex
The OpenAlex for M. Catherine Pietanza is on the source record.
What are the most-cited papers on M. Catherine Pietanza?
ScholarIQmost cited works
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Dómine, Philip R. Clingan, Maximilian J. Hochmair, Steven Powell, Susanna Y. Cheng, Helge Bischoff, Nir Peled, Francesco Grossi, Ross Jennens, Martin Reck, Rina Hui, Edward B. Garon, Michael Boyer, Belén Rubio‐Viqueira, Silvia Novello, Takayasu Kurata, Jhanelle E. Gray, John Vida, Ziwen Wei, Jing Yang, Harry Raftopoulos, M. Catherine Pietanza, Marina Chiara Garassino
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer
Shirish M. Gadgeel, Delvys Rodríguez‐Abreu, Giovanna Speranza, Emilio Esteban, Enriqueta Felip, Manuel Dómine, Rina Hui, Maximilian J. Hochmair, Philip R. Clingan, Steven Powell, Susanna Y. Cheng, Helge Bischoff, Nir Peled, Francesco Grossi, Ross Jennens, Martin Reck, Edward B. Garon, Silvia Novello, Belén Rubio‐Viqueira, Michael Boyer, Takayasu Kurata, Jhanelle E. Gray, Jing Yang, Tuba Öcek Baş, M. Catherine Pietanza, Marina Chiara Garassino
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
Marina Chiara Garassino, Shirish M. Gadgeel, Giovanna Speranza, Enriqueta Felip, Emilio Esteban, Manuel Dómine, Maximilian J. Hochmair, Steven Powell, Helge Bischoff, Nir Peled, Francesco Grossi, Ross Jennens, Martin Reck, Rina Hui, Edward B. Garon, Takayasu Kurata, Jhanelle E. Gray, Paul Schwarzenberger, Erin Jensen, M. Catherine Pietanza, Delvys Rodríguez‐Abreu
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
Laura R. Saunders, Alexander J. Bankovich, Wade Anderson, Monette Aujay, Sheila Bheddah, KristenAnn Black, Radhika Desai, Paul A. Escarpe, Johannes Hampl, Amy Laysang, David Liu, Javier Lopez-Molina, Milly Milton, Albert Park, Marybeth A. Pysz, Hui Shao, Brian C. Slingerland, Michael Torgov, Samuel A. Williams, Orit Foord, Philip W. Howard, Jacek Jassem, A. Badzio, Piotr Czapiewski, David H. Harpole, Afshin Dowlati, Pierre P. Massion, William D. Travis, M. Catherine Pietanza, John T. Poirier, Charles M. Rudin, Robert Stull, Scott J. Dylla
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
Charles M. Rudin, M. Catherine Pietanza, Todd M. Bauer, Neal Ready, Daniel Morgensztern, Bonnie S. Glisson, Lauren A. Byers, Melissa L. Johnson, Howard A. Burris, Francisco Robert, Tae Hyung Han, Sheila Bheddah, Noah Theiss, Sky Watson, Deepan Mathur, Bharathi Vennapusa, Hany Zayed, Satwant Lally, Donald K. Strickland, Ramaswamy Govindan, Scott J. Dylla, Stanford L. Peng, David R. Spigel